Glenmark Pharmaceuticals has received final USFDA approval for generic version of Desonide cream, used to treat a variety of skin conditions. The Desonide Cream, 0.05 per cent is the generic version of Perrigo New York Inc. According to IMS Health sales data for the 12 months to May 2017, Desonide Cream, 0.05 per cent, achieved annual sales of approximately USD 44.6 million. The company’s current portfolio consists of 120 products authorised for distribution in the US marketplace and 65 Abbreviated New Drug Applications (ANDA) pending approval with the USFDA.
Company Profile : Glenmark Pharma Ltd
Leave a Reply